Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vertex PharmaceuticalsMEX:VRTX -2.11%90 3-Year Book Growth Rate is 10.70% as of Jun. 2026, which is 29% below its 10-year median of 15.10. GuruFocus rates MEX:VRTX with a GF Score™ of 90/100 and a GF Value™ of MXN8,999.13 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,126 Biotechnology companies, Vertex Pharmaceuticals ranks better than 78.33% on this metric.
During the past 12 months, Vertex Pharmaceuticals's average Book Value per Share Growth Rate was 19.30% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 10.70% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 17.30% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 36.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Vertex Pharmaceuticals was 97.50% per year. The lowest was -58.90% per year. And the median was 15.10% per year.
Vertex Pharmaceuticals (MEX:VRTX) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Vertex Pharmaceuticals 3-Year Book Growth Rate Related Terms
MEX:VRTX vs REGN, MRNA, RVMD: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's 3-Year Book Growth Rate falls into.
Vertex Pharmaceuticals 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 10.70% mean?
Vertex Pharmaceuticals (MEX:VRTX) has a 3-Year Book Growth Rate of 10.70% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Vertex Pharmaceuticals and its competitors. This is 29% below median its historical median of 15.10. According to the industry distribution chart, Vertex Pharmaceuticals ranks #244 out of 1126 companies in the Biotechnology industry, placing it in the top 21.7%.
Is Vertex Pharmaceuticals' 3-Year Book Growth Rate too high?
Vertex Pharmaceuticals' current 3-Year Book Growth Rate of 10.70% is 29% below median its 10-year median of 15.10. Based on the distribution chart, Vertex Pharmaceuticals ranks #244 out of 1126 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vertex Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' 3-Year Book Growth Rate compare to REGN and MRNA?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #244 out of 1126 companies for 3-Year Book Growth Rate. This places Vertex Pharmaceuticals in the top 22% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current 3-Year Book Growth Rate is 10.70%, which is 29% below median its own 10-year median of 15.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (MEX:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is MXN8,999.13, compared to a current price of MXN9,265.00 — trading 3% above its estimated fair value. The current 3-Year Book Growth Rate is 10.70%, which is 29% below median its 10-year median of 15.10. Vertex Pharmaceuticals' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Vertex Pharmaceuticals (MEX:VRTX), the current 3-Year Book Growth Rate is 10.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (MEX:VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN9,265.00 is trading 3% above its estimated GF Value™ of MXN8,999.13.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:VRTX:
3-Year Book Growth Rate: 10.70% (29% below median its 10-year median of 15.10)
GF Value™: MXN8,999.13 vs. price of MXN9,265.00 (3% above fair value)
No single metric tells the full story. See the MEX:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
90GF Score
Get the complete analysis for MEX:VRTX
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VRTX has been successfully added to your 
